Keytruda powers Merck to first-quarter beat

(Reuters) – Drugmaker Merck & Co reported a better-than-expected first-quarter profit on Tuesday and raised its adjusted earnings forecast for the year, helped by a more than 150 percent rise in sales of cancer drug Keytruda.

…read more

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

Source:: Reuters – Business News